Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility

In asthma, the type 2 inflammatory response mediated by IgE leads to airway remodeling and subsequent symptom presentation.1 Blocking the action of IgE can decrease airway remodeling, including reducing wall thickness and inflammation.2,3 Airway smooth muscle thickness and vascularity are inversely correlated with postbronchodilator FEV1.4 In patients with allergic asthma, bronchodilator reversibility can indicate pulmonary function and is associated with lung function improvement during omalizumab therapy.